Clinical Trials Sponsored by Akebia Therapeutics

Total 6321 results

Akebia Therapeutics

Completed

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Anemia Associated With Chronic Kidney Disease (CKD)

United States
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Portugal, Russian Federation, Ukraine, Poland, Argentina, Brazil, Germany, Mexico
Akebia Therapeutics

Completed

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Anemia | End Stage Renal Disease

United States
Akebia Therapeutics

Completed

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

Chronic Kidney Disease

United States
Akebia Therapeutics

Terminated

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

Healthy

United States
Akebia Therapeutics

Completed

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Pharmacokinetics | Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

Healthy

United States
Akebia Therapeutics

Withdrawn

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILOGY)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease (CONVERSION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Kidney Disease

United States
Akebia Therapeutics

Completed

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Kidney Disease

United States
Akebia Therapeutics

Completed

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Australia, New Zealand, South Africa, United Kingdom, Spain, Ukraine, Hungary, Israel, Bulgaria, Russian Federation, Mexico, Poland, Brazil, Argentina, Malaysia, Puerto Rico, France
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Completed

Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

Healthy Volunteers

Canada
Akebia Therapeutics

Completed

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Anemia Associated With Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

Healthy Volunteers

United States
Akebia Therapeutics

Completed

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

Healthy Volunteers

United States
Akebia Therapeutics

Completed

Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

Healthy Volunteers
Akebia Therapeutics

Completed

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa (FO2RWARD-2)

Anemia | Dialysis-dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults

Healthy

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

Drug Interaction Potentiation

Canada
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
USRC Kidney Research
Akebia Therapeutics

Active, not recruiting

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease (FRONTIER)

Disease Progression | Renal Insufficiency, Chronic | Hyperphosphatemia | Anemia, Iron Deficiency | Renal Anemia | Iron | Cardiovascular

United States
USRC Kidney Research
Akebia Therapeutics Inc.

Completed

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants (IMPACT)

Renal Insufficiency | Hyperphosphatemia | Anemia, Iron Deficiency

United States
Akebia Therapeutics
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Anemia

United States, Italy, Spain, Hungary, Czechia, Poland
Aktiia SA

Not yet recruiting

Evaluation of the Performance and Safety of the Aktiia Spot-check Optical Blood Pressure Monitoring (OBPM) Device at Fingertip (Aktiia G2C) Against Double Auscultation, and Comparison With Oscillometry and Aktiia Bracelet G2: a Single-center Prospective Clinical Study

Hypertension

Switzerland
Aktiia SA

Recruiting

Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (OBPM_Meds2023)

Hypertension

Switzerland
Aktiia SA

Not yet recruiting

Continual vs. Routine Home Blood Pressure Monitoring and Management in Diverse Community Practice: CHANGE-BP (CHANGE-BP)

Hypertension

United States
Aktiia SA

Completed

COOL-BP Study: Continuous Versus Occasional Blood Pressure Study

Hypertension

United States
The University of Texas Health Science Center,...
United States Department of Defense; Akebia Therapeutics Inc.

Completed

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Coronavirus Infection | Acute Respiratory Distress Syndrome

United States
Aktiia SA

Not yet recruiting

Evaluation of the Satisfaction of a Hypertensive Population in Their Use of the Aktiia 24/7 Blood Pressure Monitor (OBPM_HTN2024)

Hypertension
Aktiia SA

Recruiting

Performance of the Aktiia Optical Blood Pressure Monitoring Device Against Double Auscultation

Hypertension | Blood Pressure | Heart Rate

Switzerland
Stem Cells Arabia

Unknown

Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy

Cerebral Palsy
Stem Cells Arabia

Unknown

Transplantation of Autologous Bone Marrow or Leukapheresis-Derived Stem Cells for Treatment of Spinal Cord Injury

Spinal Cord Injury

Jordan
Stem Cells Arabia

Unknown

Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells

Use of Stem Cells for COVID-19 Treatment

Jordan
Stem Cells Arabia

Unknown

Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis

Osteoarthritis, Knee | Osteoarthritis, Hip | RheumatoId Arthritis
Stem Cells Arabia

Unknown

Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.

Multiple Sclerosis

Jordan
Stem Cells Arabia

Unknown

Autologous Bone Marrow-Derived CD34+, CD133+, and CD271+ Stem Cell Transplantation for Retinitis Pigmentosa

Retinitis Pigmentosa

Jordan
Stem Cells Arabia

Unknown

Bone Marrow-Derived Autologous Stem Cells for the Treatment of Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy

Jordan
Stem Cells Arabia

Unknown

Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells

Optic Neuropathy

Jordan

3

Subscribe